CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
